Search & Regulation: One Click Rule, RIP

Share this article:

The use of paid search by pharmas crashed in the aftermath of DDMAC's issuance of 14 enforcement letters for sponsored links a year ago. Exposures plummeted by 59% within a week of March 26, 2009, when the letters were sent out, and were down 84% by the end of June, but have since crept back, according to comScore data. However, with the agency's elimination of the “one click rule” —an unwritten assumption that so long as full-risk information was a click away, marketers were OK —has wrought changes in how pharmas do search.

First of all, sponsored links sending viewers to so-called vanity URLs, bearing the name of a campaign rather than a product, have largely replaced brand.com links, even if that's where you end up.

“It's the accepted method that everyone's gone to,” says John Mangano, VP at comScore.

The agency's beef, basically, was with sponsored links being treated differently than any other form of advertisement discussing both a brand and the condition it treats, in which full-risk information must be disclosed front and center.

“Prior to the letters, many advertisers were running search ads both with brand,” says Google head of industry for health Amy Cowan, “and now all have moved to running only branded or only unbranded.”

The shift is important because it means the uncoupling of brand and condition in searches, says comScore's Mangano. Now, if you can't remember the name of the brand in the ad you saw and you instead search on a condition for which there are multiple therapies, you're likely to get a stack of vanity URLs and land on a brand.com site for a rival product.

At DDMAC's hearings on online promotion of pharmaceuticals back in November, Google unveiled proposed formats for sponsored links. The formats—one for links making product claims and the other for those carrying a black-box warning—weren't cleared with FDA in advance, since only drug companies can submit materials to the agency for preapproval. But the black-box format has since been green-lighted by the agency and is now in use by Bayer for Yaz, Lilly for Symbyax and Strattera, and Amgen for Enbrel.

The format is that of a branded link, sans product claim, but with a fixed line below advising: “Click to see full safety and prescribing information, including boxed warning,” and an additional “More info” link.

Google's Cowan says that advertisers are getting comfortable with sponsored links again after a nasty shock. “In terms of sentiment, we have seen that people are enthusiastic about digital for 2010 and having paid search as a central part of their strategy,” said Cowan.


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.